ATX inhibitors have been tested in a variety of cancers, including breast cancer (Tang et al. 2020), lung cancer (Bhave et al. 2013), colorectal cancer (Yun 2019), and melanoma (Jankowski 2011). This evidence concerns the gene ENPP2 and melanoma.